← Back to Clinical Trials
Recruiting NCT06910969

NCT06910969 Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06910969
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Bone Marrow Transplant Complications
Study Type INTERVENTIONAL
Enrollment 350 participants
Start Date 2025-08-13
Primary Completion 2029-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
HORIZONS InterventionMinimally enhanced usual care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 350 participants in total. It began in 2025-08-13 with a primary completion date of 2029-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.

Eligibility Criteria

Inclusion Criteria: * Adult patients (≥ 18 years) who have undergone allogeneic HCT * Have moderate to severe cGVHD based on patient-report * Have ability to participate in English or Spanish language group telehealth intervention. Exclusion Criteria: * Patients with mild cGVHD based on their self-report. * Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent. * Patients with active relapsed disease requiring therapy.

Contact & Investigator

Central Contact

Lara Traeger PhD

✉ ltraeger@miami.edu

📞 304-284-3012

Principal Investigator

Areej El-Jawahri MD

PRINCIPAL INVESTIGATOR

Massachusetts General Hospital

Frequently Asked Questions

Who can join the NCT06910969 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Marrow Transplant Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06910969 currently recruiting?

Yes, NCT06910969 is actively recruiting participants. Contact the research team at ltraeger@miami.edu for enrollment information.

Where is the NCT06910969 trial being conducted?

This trial is being conducted at Miami, United States, Boston, United States.

Who is sponsoring the NCT06910969 clinical trial?

NCT06910969 is sponsored by Massachusetts General Hospital. The principal investigator is Areej El-Jawahri MD at Massachusetts General Hospital. The trial plans to enroll 350 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology